Dewei Tang

Dewei Tang

Auto-generated profile, based on publicly available information

Dewei Tang

Shanghai Jiao Tong University School of Medicine

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
FDFan Ding
Fan Ding
CHChen Huang
Chen Huang
CLChenyi Liang
Chenyi Liang
CWCheng Wang
Cheng Wang
JLJianjun Liu
Jianjun Liu
DTDewei Tang
Dewei Tang

4 June 2018 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
DTDewei Tang
Dewei Tang
JLJun Li
Jun Li
MNMichael L. Nickels
Michael L. Nickels
GHGang Huang
Gang Huang
ACAllison S. Cohen
Allison S. Cohen
HMH. Charles Manning
H. Charles Manning

1 December 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MLMiaomiao Li
Miaomiao Li
CHChen Huang
Chen Huang
XWXingyu Wu
Xingyu Wu
FDFan Ding
Fan Ding
ZHZhoumi Hu
Zhoumi Hu
DTDewei Tang
Dewei Tang

26 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
FDFan Ding
Fan Ding
CHChen Huang
Chen Huang
CLChenyi Liang
Chenyi Liang
CWCheng Wang
Cheng Wang
JLJianjun Liu
Jianjun Liu
DTDewei Tang
Dewei Tang
Purpose: This longitudinal study aims to evaluate the performance of 68 Ga-FAPI-04 and 18 F-FDG and to profile the dynamic process of tumor metastasis in a preclinical 4T1 breast cancer model. Although both of these two radioligands are wildly used in clinic, no study was reported on their performance in the longitudinal monitoring of tumor metastasis. Also, no correlation between the expression level of fibroblast activation protein (FAP) and the development of tumor metastasis has been elucidated previously. In this study, we evaluated the performance of 68 Ga-FAPI-04 and 18 F-FDG PET during the entire process of tumor metastasis, and their potential for the early diagnosis of tumor metastasis. We also clarified the correlation of uptakes as well as the signal-to-background (S/B) ratios between these two probes at different stages of tumor metastasis. Methods: Forty 4T1 metastatic breast cancer murine model were established using female BALB/c mice, followed by the longitudinal imaging with 68 Ga-FAPI-04 and 18 F-FDG once a week for up to six weeks. In vitro Hematoxylin & Eosin (H&E) and immunochemistry (IHE) staining were performed to evaluate FAP expression on the metastatic lesions. Further statistical analysis was performed to evaluate the correlation of 68 Ga-FAPI-04 and 18 F-FDG uptake (%ID/cc) at different stages of the metastasis. Results: 68 Ga-FPAI-04 holds an advantage over 18 F-FDG with higher sensitivity at the early stage of tumor metastasis. However, with the progress of tumor metastasis, uptake of 68 Ga-FAPI-04 decreases and becomes less sensitive than 18 F-FDG. There is also no direct correlation between uptake or S/B ratios of 68 Ga-FAPI-04 and 18 F-FDG during this dynamic process. Conclusion: 68 Ga-FAPI-04 is more sensitive than 18 F-FDG in detecting the early stage of tumor metastasis, but becomes less sensitive than 18 F-FDG at the late stage of tumor metastasis. We envision this result would be meaningful for the explanation of the 18 Ga-FAPI-04 and 18 F-FDG imaging both in the future clinic and preclinic studies.

11 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
CHChen Huang
Chen Huang
FDFan Ding
Fan Ding
YHYong Hao
Yong Hao
ZHZhoumi Hu
Zhoumi Hu
CWCheng Wang
Cheng Wang
DTDewei Tang
Dewei Tang
Purpose: Translocator protein (TSPO), an outer mitochondrial membrane protein, is regarded as a key biomarker for neuroinflammation in a variety of neurodegenerative diseases. In this study, we aim to evaluate two highly specific TSPO radiotracers [18F]VUIIS1009A and [18F]VUIIS1009B in a mild cerebral ischemic rat model, and to compare their in vivo performance to the well-established TSPO probe [18F]DPA-714 for neuroinflammation imaging. With multiple graphic analytical methods tested and macro parameters determined, we propose to find a suitable and best quantification method to profile neuroinflammation and measure TSPO density with the three TSPO radiotracers.Methods: Cerebral ischemia rat model was created and imaged using [18F]VUIIS1009A, [18F]VUIIS1009B and [18F]DPA-714. Displacement studies using non-radioactive analogs were performed to evaluate the binding specificities of [18F]VUIIS1009A and [18F]VUIIS1009B individually. Imaging analysis using arterial plasma input functions (AIFs) was employed to generate Logan plots and parametric images of total distribution volume (VT) for each radiotracer. Reference Logan model using contralateral brain as a reference region was introduced to generate parametric images for binding potential (BPND). Results: When compared to [18F]DPA-714, [18F]VUIIS1009B demonstrated higher binding potential (BPND) and distribution volume ratio (DVR). Parameter images of BPND and VT also indicate [18F]VUIIS1009B has a superior imaging profile with higher BPND and DVR when compared with other two radiotracers in TSPO imaging. Correlation analysis between BPND for [18F]VUIIS1009B and [18F]DPA-714 also indicates [18F]VUIIS1009B is more sensitive than [18F]DPA-714 in TSPO density measurement.Conclusions: This study demonstrates the superiority of [18F]VUIIS1009B to [18F]VUIIS1009A and [18F]DPA-714 in the neuroinflammation imaging. It also demonstrates that [18F]VUIIS1009B PET imaging coupled with parameter mapping (VT and BPND) and graphic analysis using Logan analysis and reference Logan analysis holds great promise for neuroinflammation characterization and TSPO density measurement.